UK’s Aspire Acquired By HIG
Aspire CEO Talks About Expanding Geographical Footprint
UK firm Aspire, known for producing niche generics and specialty products, has found new ownership after being acquired by investment firm HIG Capital. Talking exclusively to Generics Bulletin, Aspire founder and CEO Graham Fraser-Pye, now chairman of the company, said that HIG would help Aspire grow and support new initiatives such as mergers and acquisitions and international expansion.
You may also be interested in...
South Korea’s Celltrion delivered a relatively weak quarter in Q3, with a 26.9% drop in revenues despite robust sales of Truxima (rituximab) and Remsima (infliximab). The company also voiced confidence in pro-biosimilar policies introduced by the Biden administration in the US.
The Indian Pharmaceutical Alliance’s recent Global Innovation Summit 2021 saw regulatory and industry bodies call for policy intervention to provide support and incentives for innovation and R&D in the Indian pharmaceutical sector. Inaugurated by the Indian prime minister Narendra Modi, the summit saw Modi invite “everyone to ideate in India, innovate in India and make in India and make for the world.”
India’s JB Chemicals has seen double-digit growth in its international business and “market beating growth” in its domestic business. The company continues to perform well on the back of new launches, despite COVID-related headwinds.